Sunday 18 October 2026
Export IRD’s income statement to Excel — free account
Opus Genetics, Inc.
Opus Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.2 million, up 29.1% from fiscal 2024. In the quarter to June 2026, revenue fell 73.8%, EPS grew 33.3% and free cash flow fell 16.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.81
0.24
−5.93%
Follow IRD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 3 | 5 | 2 |
+8 more TTM periods Free account |
| (4,796.52%) | 524.65% | (449.36%) | (338.75%) | ||
| (163.50%) | (186.04%) | (113.86%) | (178.28%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(126.21%) | (186.14%) | (116.79%) | (969.48%) | |
Average Days of Receivables |
38.55 | 52.73 | 51.29 | 72.74 | |
Free Cash Flow per Share |
(0.43) | (0.45) | (0.57) | (0.47) | |
Free Cash Flow |
(40.67) | (38.99) | (35.25) | (32.86) | |
| Other line items | |||||
Cash ROIC |
(36.72%) | (276.05%) | (58.33%) | (86.81%) | |
Accounts Receivable Turnover |
4.44 | 4.98 | 5.11 | 6.13 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
391.85% | 279.03% | 217.05% | 378.72% | |
Selling, General and Administrative Expense of Revenue |
221.62% | 180.10% | 154.85% | 166.68% | |
Share Based Compensation of Revenue |
45.26% | 32.96% | 23.94% | 23.37% | |
Interest Coverage |
— | (76.17) | (77.82) | (148.46) | |
Operating CF/Net income |
0.38 | 0.36 | 0.71 | 0.48 | |
Depreciation/Fixed assets |
0.31 | 0.28 | 0.27 | 0.24 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.10 | 0.14 | 0.23 | 0.21 | |
Operating CF per Share |
(0.43) | (0.45) | (0.57) | (0.47) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates